Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty

Faculty

Keith A. Betts, PhD

Vice President

Analysis Group

Los Angeles, CA

David Z. I. Cherney, MD, PhD

Professor of Medicine

University of Toronto

Toronto, ON

Yuxian Du, PhD

Manager

Research Strategy, Data Generation and

Observational Studies

Bayer Pharmaceuticals

Whippany, NJ

Elizabeth Faust, MBA, MPH

Manager

Analysis Group

New York, NY

Kerstin Folkerts, MSc

HEOR Senior Project Manager

HEOR Cardio, Renal, & Vascular Diseases

Bayer AG

Wuppertal, Germany

Linda F. Fried, MD, MPH

Professor of Medicine

Epidemiology, and Clinical & Translational Science

Associate Professor of Epidemiology

University of Pittsburgh

Pittsburgh, PA

Staff Physician, Renal Section

VA Pittsburgh Healthcare System

Pittsburgh, PA

Sheldon X. Kong, PhD

Executive Director

Research Strategy, Data Generation

and Observational Studies

Bayer Pharmaceuticals

Whippany, NJ

Csaba P. Kovesdy, MD

The Fred Hatch Professor of Medicine

Department of Medicine

Division of Nephrology

University of Tennessee Health Science Center

Memphis, TN

Pierre Levy, PhD

LEDa[LEGOS]

Université Paris-Dauphine

Paris, France

Paul Mernagh, MCom

Project leader, HEOR

Cardio, Renal, & Vascular Diseases

Bayer AG

Berlin, Germany

Aurélie Millier, PhD

Vice President

Health Economics and Outcomes Research

Creativ-Ceutical

Paris, France

Stephen Morris, PhD

RAND Professor of Health Services Research

Deputy Director

Primary Care Unit

Department of Public Health and Primary Care

University of Cambridge

Cambridge, UK

Natalia Petruski-Ivleva, PhD

Associate Director

Science

Aetion

Boston, MA

Michał T. Pochopien´, MSc

HEOR Principal

Creativ-Ceutical

Kraków, Poland

Prabir Roy-Chaudhury, MD, PhD

Director

University of North Carolina Kidney Center

Chapel Hill, NC

Professor of Medicine

University of North Carolina at Chapel Hill

Chapel Hill, NC

Niklas Schmedt, DrPH

Senior Outcomes Data Expert

Integrated Evidence Generation

& Business Innovation

Bayer AG

Berlin, Germany

Rakesh Singh, PhD

Director

Research Strategy, Data Generation

and Observational Studies

Bayer Pharmaceuticals

Whippany, NJ

Jinlin Song, PhD

Manager

Analysis Group

Los Angeles, CA

Sean D. Sullivan, PhD

Professor and Dean, School of Pharmacy

University of Washington

Seattle, WA

Priscilla Velentgas, PhD

Senior Principal

Real World Solutions

IQVIA

Cambridge, MA

Karen Yang, BA

Senior Analyst

Analysis Group

New York, NY

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Keith A. Betts, PhD

EMPLOYMENT

Employee of Analysis Group, a consulting

company that has provided paid consulting

services to Bayer Pharmaceuticals, which

funded the development and conduct of this

study and manuscript

David Z. I. Cherney, MD, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

Boehringer Ingelheim-Lilly, Merck,

AstraZeneca, Sanofi, Mitsubishi-Tanabe,

AbbVie, Janssen, Bayer Pharmaceuticals,

Prometic, Bristol Myers Squibb, Maze,

CSL-Berhring, and Novo-Nordisk

GRANTS RECEIVED

Boehringer Ingelheim-Lilly, Merck, Janssen,

Sanofi, AstraZeneca, and Novo-Nordisk

Yuxian Du, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

Received consulting fees from faculty emeritus

at the University of Washington

EMPLOYMENT

Employee of Bayer Pharmaceuticals,

sponsor of the study

STOCK OWNERSHIP

Bayer Pharmaceuticals, sponsor of the study

INSTITUTIONAL CONFLICTS OF INTEREST

Bayer Pharmaceuticals drug for chronic

kidney disease in patients with type 2 diabetes

approved in the United States

Elizabeth Faust, MBA, MPH

INSTITUTIONAL CONFLICTS OF INTEREST

Employee of Analysis Group, a consulting

company that has provided paid consulting

services to Bayer Pharmaceuticals, which

funded the development and conduct of this

study and manuscript

Kerstin Folkerts, MSc

EMPLOYMENT

Employee of Bayer AG, sponsor of the study

STOCK OWNERSHIP

Holding stocks and stock options from Bayer

AG, sponsor of the study

INSTITUTIONAL CONFLICTS OF INTEREST

Bayer Pharmaceuticals drug for chronic

kidney disease in patients with type 2 diabetes

approved in the United States

Linda F. Fried, MD, MPH

CONSULTANCIES OR PAID ADVISORY BOARDS

Consultant to Bayer Pharmaceuticals

Sheldon X. Kong, PhD

EMPLOYMENT

Employee of Bayer Pharmaceuticals

STOCK OWNERSHIP

Employee of Bayer Pharmaceuticals

with stock options

INSTITUTIONAL CONFLICTS OF INTEREST

Employee of Bayer Pharmaceuticals, which

produces Kerendia (finerenone) for the

treatment of chronic kidney disease associated

with type 2 diabetes

Csaba P. Kovesdy, MD

CONSULTANCIES OR PAID ADVISORY BOARDS

Consultant for AstraZeneca, Bayer

Pharmaceuticals

HONORARIA

Honoraria for consultant work from

AstraZeneca, Bayer Pharmaceuticals

Pierre Levy, PhD

HONORARIA

Honoraria received from Bayer

Pharmaceuticals for ad boards related to

the development of an economic model

for finerenone

Paul Mernagh, MCom

CONSULTANCIES OR PAID ADVISORY BOARDS

Previously an independent consultant

for Bayer Pharmaceuticals

EMPLOYMENT

Bayer AG employee

INSTITUTIONAL CONFLICTS OF INTEREST

Subject matter will be used to support market

launch of finerenone, which is produced by

Bayer Pharmaceuticals

Stephen Morris, PhD

HONORARIA

Honorarium from Bayer Pharmaceuticals for

participation in current manuscript

Prabir Roy-Chaudhury, MD, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

Consultant/Advisory Board for WL Gore,

Becton, Dickinson, and Company, Medtronic,

Humacyte, Cormedix, Akebia, Vifor-Relypsa,

Bayer Pharmaceuticals

Niklas Schmedt, DrPH

EMPLOYMENT

Employee of Bayer AG

INSTITUTIONAL CONFLICTS OF INTEREST

Bayer Pharmaceuticals drug for chronic

kidney disease in patients with type 2 diabetes

approved in the United States

Rakesh Singh, PhD

EMPLOYMENT

Employee of Bayer Pharmaceuticals,

sponsor of the study

STOCK OWNERSHIP

Bayer Pharmaceuticals, sponsor of the study

INSTITUTIONAL CONFLICTS OF INTEREST

Bayer Pharmaceuticals drug for chronic

kidney disease in patients with type 2 diabetes

approved in the United States

Jinlin Song, PhD

EMPLOYMENT

Employee of Analysis Group, a consulting

company that has provided paid consulting

services to Bayer Pharmaceuticals, which

funded the development and conduct of this

study and manuscript

Sean D. Sullivan, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer AG supported by time to assist with

model development

Priscilla Velentgas, PhD

EMPLOYMENT

Employee of IQVIA, which conducts research

for all of the world’s biopharma companies

Karen Yang, BA

INSTITUTIONAL CONFLICTS OF INTEREST

Employee of Analysis Group, a consulting

company that has provided paid consulting

services to Bayer Pharmaceuticals, which

funded the development and conduct of this

study and manuscript

Aurélie Millier, PhD; Natalia Petruski-Ivleva, PhD; and Michał T. Pochopien´, MSc,

report no relationships or financial interests with

any entity that would pose a conflict of interest

with the subject matter of this supplement.

Download PDF